Erschienen in:
13.10.2021 | Correction
Correction to: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program
verfasst von:
Eric L. Simpson, Jonathan I. Silverberg, Audrey Nosbaum, Kevin L. Winthrop, Emma Guttman-Yassky, Karin M. Hoffmeister, Alexander Egeberg, Hernan Valdez, Min Zhang, Saleem A. Farooqui, William Romero, Andrew J. Thorpe, Ricardo Rojo, Susan Johnson
Erschienen in:
American Journal of Clinical Dermatology
|
Ausgabe 6/2021
Einloggen, um Zugang zu erhalten
Excerpt
The article was originally published electronically on SpringerLink on 18 August 2021. After publication in volume 22, issue 5, pages 693–707, the authors highlighted that, in Supplemental Table 1, the overall patient numbers for the JADE MONO-2 and JADE COMPARE studies were incorrect. These errors have been rectified and a new corrected version of Supplementary file 1 has been uploaded with the manuscript on SpringerLink. …